Out-of-Pocket Costs and Prescription Reversals With Oral Linezolid | Page 1
Published Online: September 18, 2013
Margaret K. Pasquale, PhD; Anthony M. Louder, PhD, RPh; Michael C. Deminski, MS, RPh; Richard B. Chambers, MSPH; and Seema Haider, MSc
Linezolid is indicated for the treatment of vancomycin-resistant Enterococcus faecium infections, complicated and uncomplicated skin and soft tissue infections (SSTIs), and nosocomial and community-acquired pneumonia (eAppendix available at www.ajmc.com).1 Pathogens for such infections include Staphylococcus aureus (methicillin-susceptible and resistant strains), Streptococcus pneumoniae (including multidrug-resistant strains), Streptococcus pyogenes, and Streptococcus agalactiae. Among these, methicillin-resistant Staphylococcus aureus (MRSA) infections have received particular attention in the 2000s commensurate with evidence indicating a dramatic rise in the rate of MRSA-related hospital admissions.2-4 Whereas more recent studies suggest community-onset and hospital-onset MRSA infections may have tapered and declined somewhat since 2005,5,6 the burden of SSTIs overall remains substantial, and if these infections are not appropriately treated they can result in serious life-threatening consequences.
Among antibiotics used to treat SSTIs and pneumonia, linezolid is available in both intravenous and oral forms. Oral bioavailability is approximately 100%,1 allowing for sequential intravenous to oral administration without changing the drug or dosing regimen. The availability of intravenous and oral forms may allow for a shortened length of hospital stay if treatment is continued orally after discharge, resulting in lower total costs of treating the infection.7 However, due to oral linezolid’s high out-of-pocket costs, patients have been known to decline purchase of (reversals) their prescriptions and receive treatment with an alternative antibiotic or forgo treatment altogether.8
Previous research by Ball and colleagues7 based on Humana Inc health plan members examined whether rehospitalization rates and total healthcare costs increased for members with a prescription reversal versus a fill of oral linezolid. Although members with a claim reversal were rehospitalized at higher rates and had higher medical costs compared with those who had a fill, they did not have higher total healthcare costs than members with a prescription fill for oral linezolid. This implied that oral linezolid and alternative antibiotics or the absence of treatment were similarly cost-effective. However, one limitation of the study by Ball and colleagues was that diagnosis for the initial hospitalization was not confirmed for an infection indicated for linezolid treatment. A second limitation of the study by Ball and colleagues was that members were followed for as long as 60 days postdischarge, which potentially led to inclusion of healthcare utilization and costs unrelated to the initial infection and its consequences.
This research sought to refine the study by Ball and colleagues by restricting the identification of members to those whose initial hospitalization was for complicated or uncomplicated SSTI or pneumonia diagnoses (eAppendix), as well as shortening the postdischarge time period to 30 days to examine acute consequences more likely related to the initial hospitalization. Members from both commercial and Medicare lines of business were initially identified for the study, but all analyses were conducted separately by line of business because of significant differences in plan reimbursement. This study focuses on the Medicare line of business, which comprised a majority (71%) of the total membership.
This study utilized data from Humana’s SAS database which contains enrollment, medical, and pharmacy claims data for Humana’s Medicare membership. All data sources were merged using de-identified member data. The finalized protocol was approved by a central independent institutional review board.
We performed a retrospective cohort analysis of all Medicare members identified as having a prescription claim for oral linezolid after discharge from an inpatient stay for complicated or uncomplicated SSTI or pneumonia (eAppendix).Members were identified during the time period of June 1, 2007, to April 30, 2011. The service date of the first linezolid prescription claim was used to identify the date of the index event (fill or reversal). Members who were identified with a reversal in the pharmacy claims but who filled the prescription for oral linezolid within 3 days after the reversal were recategorized as fill members. Members with a claim reversal were compared with those without a reversal in terms of plan design (whether members paid a copay or had coinsurance), member out-of-pocket costs, infection-related (complicated or uncomplicated SSTI or pneumonia) and all-cause rehospitalization (inpatient admission with overnight stay), and healthcare costs (prescription, medical, and total) in the 30 days post discharge.
Study subjects were fully insured Medicare Advantage members aged 18 to 89 years who were continuously enrolled for 120 days before and 30 days after the index event (linezolid fill or reversal) and whose index linezolid claim was processed no more than 2 days before or 10 days after hospital discharge. A diagnosis of complicated or uncomplicated SSTI or pneumonia in any position on the inpatient claim was required for the initial hospitalization.
Members were excluded from analysis if they were enrolled as administrative services–only populations (members of employer-funded plans excluded by contract from research), had a claim for pregnancy (International Classification of Diseases, Ninth Revision codes 630.xx-679.xx, V22.xx, and V23.xx), or were in a skilled nursing facility/nursing home any time during the study period.
PDF is available on the last page.